Skip to main content

Adimmune Corporation (TPE:4142)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
16.80
+0.10 (0.60%)
Nov 13, 2026, 1:30 PM CST
Market Cap7.08B -14.1%
Revenue (ttm)1.37B -15.1%
Net Income-143.62M
EPS-0.34
Shares Out 421.51M
PE Ration/a
Forward PE382.77
Dividendn/a
Ex-Dividend Daten/a
Volume724,640
Open16.85
Previous Close16.70
Day's Range16.75 - 17.15
52-Week Range15.65 - 22.50
Beta0.29
Analystsn/a
Price Targetn/a
Est. EarningsNov 19, 2026

About Adimmune

Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The compa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1965
Employees 564
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 4142
Full Company Profile

Financial Performance

In 2025, Adimmune's revenue was 1.40 billion, a decrease of -9.99% compared to the previous year's 1.56 billion. Losses were -239.89 million, -1.18% less than in 2024.

Financial Statements